Lupin and Aptissen announce exclusive distribution agreement of Synolis VA for Canada

Lupin and Aptissen announce exclusive distribution agreement of Synolis VA for Canada

Lupin Limited (Lupin) and Aptissen S.A. (Aptissen) announced that they have entered into a definitive distribution agreement under which Aptissen has granted Lupin the exclusive rights to market, distribute and sell the current Aptissen products in Canada. This includes immediate rights to distribute Synolis VA for the treatment of Osteoarthritis. Based on Statistics Canada, Osteoarthritis affects more than 10% of Canadians aged 15 or older.

Synolis VA (Visco-Antalgic) is the intra-articular injection product for osteoarthritis with a unique combination of Hyaluronic Acid and high concentration of Sorbitol. Synolis VA 40/80 is already approved by Health Canada and an additional strength is currently under review.

Commenting on this development, Dr. Sofia Mumtaz, President of Lupin Pharma Canada stated, “We are pleased to partner with Aptissen for marketing and distribution of Synolis VA, a branded product in Canada. This partnership helps us expand our product portfolio in the Canadian market. We remain committed to bring superior medical products and leverage our distribution strength to allow easy access to specialty medicines in the market.”

Lupin launches Clobazam Tablets

Lupin Limited (Lupin) announced the launch of Clobazam Tablets, 10 mg and 20 mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.Lupin’s Clobazam Tablets, 10 mg and 20 mg is the generic version of Lundbeck Pharms, LLC’s Onfi Tablets, 10 mg and 20 mg. It is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.Clobazam Tablets, 10 mg and 20 mg, had an annual sales of approximately USD 479 million in the US (IQVIA MAT March 2019).